Anu Connor

Vice President, Head of Oncology Search & Evaluation Ipsen Pharma

Anu Connor is Vice President, Head of Oncology External Innovation at Ipsen. In her current role, Anu and her team work closely with key scientific, clinical, and commercial functions to identify and evaluate external opportunities in oncology, both in solid tumors and hematologic malignancies, that are a strategic fit for Ipsen’s portfolio. Prior to her role at Ipsen, Anu led the Hematology Search and Evaluation Business Development team at BMS. Prior to BMS, Anu led Due Diligence, Search and Evaluation activities in the NIBR BD&L organization at Novartis. Prior to her transition to search and evaluation, Anu had roles in the toxicology/translational medicine organizations at Genentech/Roche and Novartis.

Seminars

Wednesday 9th September 2026
Pharma Icebreaker Panel Discussion: Targeted Oncology Biologics
8:00 am
  • Understanding what it takes for pharma to invest. What are the current budgetary considerations within pharma?
  • How is pharma assessing novel technologies, and where do they place within portfolios?
  • What feels differentiated in a crowded space? From pharma’s perspective, what will make something best-in-class?
Anu Connor speaker at Oncology & Immunology Innovation Partnering